LOG IN
SIGN UP
MARKET
GILD
GILD
Gilead Sciences Inc
NASDAQ
Real-time Quotes | Nasdaq Last Sale
62.36
+0.55
+0.89%
After Hours: 62.55 +0.19 +0.30% 19:55 07/01 EDT
OPEN
61.47
PREV CLOSE
61.81
HIGH
62.43
LOW
61.27
VOLUME
5.21M
TURNOVER
0
52 WEEK HIGH
74.12
52 WEEK LOW
55.90
MARKET CAP
78.22B
P/E (TTM)
17.42
1D
5D
1M
3M
1Y
5Y
Gilead reaches $33M settlement with Florida clinics in 'colossal financial fraud' case
Gilead Sciences (NASDAQ:GILD) has reached a $33M settlement...
Seekingalpha · 1d ago
Gilead Statement on U.S. Supreme Court Overturning Roe v. Wade
FOSTER CITY, Calif., June 29, 2022 /3BL Media/ - The U.S. Supreme Court delivered a decision in Dobbs v. Jackson Women’s Health Organization, which overturned the landmark 1973 Roe v. Wade ruling. ...
News Direct · 1d ago
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
Regulatory and other updates from Epizyme (MRNA) and Kezar (KZR) are a few key highlights from the biotech sector during the past week.
Zacks · 2d ago
Gilead's (GILD) Yescarta Gets EC Nod for Follicular Lymphoma
Gilead's (GILD) cell therapy, Yescarta, gets approval in Europe for a third indication- adult patients with relapsed or refractory follicular lymphoma after three or more lines of systemic therapy.
Zacks · 2d ago
Gilead Sciences (GILD) Stock Moves -0.99%: What You Should Know
Gilead Sciences (GILD) closed at $62.21 in the latest trading session, marking a -0.99% move from the prior day.
Zacks · 3d ago
$1000 Invested In Gilead Sciences 15 Years Ago Would Be Worth This Much Today
Gilead Sciences (NASDAQ:GILD) has outperformed the market over the past 15 years by 1.74% on an annualized basis producing an average annual return of 8.04%. Currently, Gilead Sciences has a market capitalization of $78.03 billion.
Benzinga · 3d ago
Gilead (GILD) Resubmits NDA for HIV Inhibitor to the FDA
Gilead (GILD) announces the resubmission of the NDA for lenacapavir, an investigational, long-acting HIV-1 capsid inhibitor, for the treatment of HIV-1 infection in the United States.
Zacks · 3d ago
Gilead Leadership Organization of Black Employees (GLOBE) Raised the Juneteenth Flag
In advance of Juneteenth, our Gilead Leadership Organization of Black Employees (GLOBE) employee resource group gathered to raise the Juneteenth flag on our Foster City campus. With this symbol of ...
News Direct · 3d ago
No Data
Learn about the latest financial forecast of GILD. Analyze the recent business situations of Gilead Sciences Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating
Based on 30 analysts
Hold
Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.
13.33%Strong Buy
23.33%Buy
60.00%Hold
3.33%Under-perform
0.00%Sell
Analyst Price Target
The average GILD stock price target is 69.21 with a high estimate of 90.00 and a low estimate of 56.00.
Current 62.36
EPS
Actual
Estimate
0.661.331.992.65
Institutional Holdings
Institutions: 2.27K
Institutional Holdings: 1.10B
% Owned: 87.75%
Shares Outstanding: 1.25B
TypeInstitutionsShares
Increased
675
94.27M
New
138
6.61M
Decreased
542
114.50M
Sold Out
208
3.36M
- Performance
- Asset Allocation
- Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.10%
Pharmaceuticals & Medical Research
+0.97%
Key Executives
Chairman/Chief Executive Officer/Director
Daniel O'Day
Chief Financial Officer
Andrew Dickinson
Executive Vice President/General Counsel/Secretary
Brett Pletcher
Executive Vice President
Flavius Martin
Executive Vice President
Taiyin Yang
Other
Johanna Mercier
Other
Merdad Parsey
Lead Director/Independent Director
Kevin Lofton
Independent Director
Jacqueline Barton
Independent Director
Jeffrey Bluestone
Independent Director
Sandra Horning
Independent Director
Kelly Kramer
Independent Director
Harish Manwani
Independent Director
Javier Rodriguez
Independent Director
Anthony Welters
No Data
No Data
About GILD
Gilead Sciences, Inc. is a biopharmaceutical company that is focused on advancing medicines to prevent and treat diseases, including human immunodeficiency virus (HIV), viral hepatitis and cancer. The Company's portfolio of products and pipeline of investigational drugs includes treatments for HIV/acquired immune deficiency syndrome (AIDS), COVID-19, liver diseases, hematology/oncology/cell therapy and other. Its products for HIV/AIDS patients include Biktarvy, Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada and Atripla. It offers Veklury to patients with COVID-19. The Company's products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Viread and Vosevi. Its products under hematology/oncology/cell therapy include Yescarta, Tecartus, Trodelvy and Zydelig. Other products include Letairis, Ranexa and AmBisome. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. The Company operates in more than 335 countries worldwide.
Webull offers kinds of Gilead Sciences, Inc. stock information, including NASDAQ:GILD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, GILD stock news, and many more online research tools to help you make informed decisions.
You can practice and explore trading GILD stock methods without spending real money on the virtual paper trading platform.